For more than two decades, oncologists treating advanced pancreatic cancer have watched new drugs fail to move the survival ...

Pancreatic cancer is one of the most difficult cancers to treat, with an overall five-year survival rate of 13%, according to ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...

Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer ...

Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.

Investigators compared cancer-specific survival rates after synchronous vs metachronous metastasis in patients with surgically treated renal cell carcinoma (RCC).

For the roughly 64,000 Americans diagnosed with pancreatic cancer each year, the prognosis remains grim — though regimens ...

The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic ...

The last time I spoke about Revolution Medicines (RVMD) it was with a Seeking Alpha article entitled "Revolution Medicines: ...

Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib ...

For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and ...

During a live event, Mark Yarchoan, MD and participants weighed new phase 3 immunotherapy combos for unresectable HCC, ...